Science Explorer Back to mapMap
Discussion
Researcher · Novo Nordisk (Denmark) · Denmark

Charles Pyke

Charles Pyke publishes mostly in Molecular Biology, Endocrinology, Diabetes and Metabolism and Cancer Research, on topics such as Protease and Inhibitor Mechanisms, Diabetes Treatment and Management and Cell Adhesion Molecules Research.

ORCID 0000-0002-7286-5009 OpenAlex
World rank
#101,871
of 7,710,434 ranked researchers
Rank in Denmark
#607
of 43,819
Works
124
Citations
10k
Citations per work
83.5
h-index
47
i10-index 74Top 4.5% in Molecular Biology
Charles Pyke

What does Charles Pyke research?

Charles Pyke's work is mostly in Medicine (32%), Biochemistry, Genetics and Molecular Biology (26%).

Everything else: 52 works · 41.9% of their workHealth Sciences: 40 works · 32.1% of their workMedicine: 40 works · 32.1% of their workEndocrinology, Diabetes and Metabolism: 16 works · 12.7% of their workHematology: 9 works · 7.4% of their workOncology: 7 works · 6.0% of their workSurgery: 7 works · 6.0% of their workLife Sciences: 32 works · 26.0% of their workBiochemistry, Genetics and Molecular Biology: 32 works · 26.0% of their workMolecular Biology: 17 works · 13.7% of their workCancer Research: 15 works · 12.3% of their workTHEIR WORKCharles Pyke124works
Life Sciences26%Health Sciences32%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else5241.9%
    1. Medicine4032.1%
    1. Biochemistry, Genetics and Molecular Biology3226.0%
  1. 1Molecular Biology14% of their works
  2. 2Endocrinology, Diabetes and Metabolism13% of their works
  3. 3Cancer Research12% of their works
  4. 4Hematology7% of their works
  5. 5Surgery6% of their works
  6. 6Oncology6% of their works

Research topics

Which keywords describe Charles Pyke's research?

The keywords of their largest research topics: Angiogenesis, Extracellular Matrix, Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, Cardiovascular Outcomes, Type 2 Diabetes, Inflammation and Cell Adhesion.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Angiogenesis613 topics
  2. Extracellular Matrix472 topics
  3. Matrix Metalloproteinases331 topic
  4. Tissue Inhibitors of Metalloproteinases331 topic
  5. Cardiovascular Outcomes311 topic
  6. Type 2 Diabetes311 topic
  7. Inflammation262 topics
  8. Cell Adhesion141 topic
  9. Fibroblast Activation Protein141 topic
  10. Integrins141 topic
  11. Tumor Microenvironment141 topic
  12. Ghrelin131 topic
  13. Leptin131 topic
  14. Pancreatic Islets131 topic
  15. ß-Cell Dysfunction131 topic
  16. Protease-Activated Receptors121 topic
  17. Thrombin121 topic
  18. Neuropeptides91 topic
  19. Receptors91 topic

Where does Charles Pyke work?

Charles Pyke's main affiliation in the publication record is Novo Nordisk (Denmark), Denmark.

How many publications and citations does Charles Pyke have?

OpenAlex counts 124 works and 10,359 citations for Charles Pyke, an h-index of 47, ranking #101,871 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Charles Pyke. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.